 <h1>Acid Reducer-Cimetidine Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cimetidine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cimetidine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Acid Reducer-Cimetidine.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cimetidine: oral liquid and tablets, parenteral injection, parenteral injection for iv infusion only</i></p><p>Side effects include:</p><p>Headache,   dizziness, somnolence, diarrhea. </p><p>With â‰¥1 month of therapy: gynecomastia.  </p><p>With IM therapy: transient pain at injection site. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cimetidine: compounding powder, intravenous solution, oral liquid, oral tablet</i></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased plasma creatinine (up to 11%)</p><p><b>Rare</b> (0.01% to 0.1%): Interstitial nephritis<sup>[Ref]</sup></p><p>Interstitial nephritis cleared with drug withdrawal.</p><p></p><p>Creatinine elevations usually occurred during the first week of treatment and were typically non-progressive, with values returning to pretreatment levels during therapy or up to 1 week after stopping treatment.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, diarrhea, flatulence, nausea, vomiting</p><p><b>Rare</b> (0.01% to 0.1%): Acute pancreatitis/pancreatitis<sup>[Ref]</sup></p><p>Pancreatitis cleared with drug withdrawal.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal pain, myalgia/reversible myalgia</p><p><b>Rare</b> (0.01% to 0.1%): Arthralgia/reversible arthralgia, exacerbation of joint symptoms, polymyositis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, drowsiness, headache<sup>[Ref]</sup></p><p>Headaches occurred more frequently in patients given 1600 mg/day compared to patients given 800 mg/day.</p><p></p><p>Somnolence and dizziness were usually mild and have been reported in patients receiving 800 to 1600 mg/day.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash/skin rashes</p><p><b>Rare</b> (0.01% to 0.1%): Hypersensitivity vasculitis</p><p><b>Very rare</b> (less than 0.01%): Epidermal necrolysis, erythema multiforme, generalized exfoliative erythroderma, reversible alopecia, severe generalized skin reactions, Stevens-Johnson syndrome</p><p><b>Frequency not reported</b>: Severe skin rash<sup>[Ref]</sup></p><p>Hypersensitivity vasculitis usually cleared with drug withdrawal.<sup>[Ref]</sup></p><h3>Other</h3><p>Fever cleared with drug withdrawal.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Tiredness</p><p><b>Rare</b> (0.01% to 0.1%): Fever<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Confusional states occurred within 2 to 3 days of starting treatment, were reversible within 3 to 4 days of stopping treatment and were more commonly reported in elderly patients and/or ill patients (e.g., renal dysfunction, organic brain syndrome).<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Confusional state, depression, hallucination</p><p><b>Frequency not reported</b>: Agitation, anxiety, disorientation, mental confusion, psychosis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatitis, reversible liver damage</p><p><b>Rare</b> (0.01% to 0.1%): Cholestatic effects, increased serum transaminases, mixed cholestatic-hepatocellular effects</p><p><b>Very rare</b> (less than 0.01%): Fatal hepatic effects</p><p><b>Frequency not reported</b>: Periportal hepatic fibrosis, severe parenchymal injury<sup>[Ref]</sup></p><p>Hepatitis and serum transaminase level elevations cleared with drug withdrawal.</p><p></p><p>Fatal hepatic effects have occurred with other histamine-2 receptor antagonists.</p><p></p><p>Severe parenchymal injury is considered highly unlikely due to the predominance of cholestatic features.</p><p></p><p>There was a report of biopsy-proven periportal hepatic fibrosis in a patient receiving this drug.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Leukopenia</p><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, aplastic anemia, decreased white blood cell counts, pancytopenia, thrombocytopenia</p><p><b>Very rare</b> (less than 0.01%): Immune hemolytic anemia<sup>[Ref]</sup></p><p>Leukopenia and/or thrombocytopenia were reversible with withdrawal of treatment.</p><p></p><p>Agranulocytosis/decreased white blood cell counts have been reported, with some events recurring upon rechallenge.  These events were more commonly reported in patients with serious concomitant illnesses and/or those who received drugs/treatments known to produce neutropenia.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Tachycardia</p><p><b>Rare</b> (0.01% to 0.1%): Atrioventricular (AV) heart block/heart block, sinus bradycardia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Reversible impotence</p><p><b>Rare</b> (0.01% to 0.1%): Urinary retention</p><p><b>Very rare</b> (less than 0.01%): Galactorrhea<sup>[Ref]</sup></p><p>Urinary retention cleared with drug withdrawal.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Gynecomastia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Allergic reactions and anaphylaxis usually cleared with drug withdrawal.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Allergic reactions, anaphylaxis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very rare</b> (less than 0.01%): Strongyloidiasis hyperinfection<sup>[Ref]</sup></p><h3>Respiratory</h3><p>In a large epidemiological study, it was suggested that patients taking histamine-2-receptor antagonists had an increased adjusted relative risk of 1.63 (95% confidence interval of 1.07 to 2.48) of developing pneumonia compared to patients who stopped treatment.  However, causal relationship between H2RA use and pneumonia has not been established.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Pneumonia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Tagamet HB (cimetidine)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Can OTC wart medicine help stop molluscum contagiosum?</li>
</ul><h2>More about Acid Reducer-Cimetidine (cimetidine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: H2 antagonists</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>GERD</li>
<li>Indigestion</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>